Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1005714

registered interest
date	12/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Sapropterin
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to NHS England’s appraisal of Kuvan, what steps his Department is taking to ensure that the cost offset of dietary treatments is considered in its economic assessment of the cost of commissioning new medicines.
tabling member constituency	Hornsey and Wood Green
tabling member printed	Catherine West
uin	190518
answer	answer is ministerial correction date of answer 20/11/2018 answer text <p>NHS England has considered a policy for Kuvan (sapropterin) at the Clinical Priorities Advisory Group (CPAG) meeting on 6/7 November. Whilst NHS England did make an estimate of the current cost of protein supplements and a potential reduction in their use if Kuvan were prescribed, this cost was not included in the analysis because commissioning responsibility for supplements rests with clinical commissioning groups and it would be unlikely that NHS England would be able to realise these savings. The cost of the potential reduction in protein supplements is also relatively modest compared to the cost of Kuvan.</p><p> </p><p>In line with its published process, the recommendations from CPAG will be considered by the Specialised Commissioning Oversight Group and the Specialised Services Commissioning Committee. A decision about whether or not Kuvan has been prioritised for funding will be published in due course.</p><p> </p><p>The National Institute for Health and Care Excellence (NICE) is currently developing technology appraisal guidance for the National Health Service on the use of Kuvan for the treatment of phenylketonuria. In developing technology appraisal guidance, NICE takes into account all the health and publicly funded social care related costs and benefits associated with the treatment, potentially including any costs from NHS funded treatments that can be avoided such as food supplements. The NICE appraisal of Kuvan is now underway and NICE expects to publish final guidance next year.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 190519 question first answered 20/11/2018 15:25:36 answering member 4067 label Biography information for Steve Brine
tabling member	4523 label Biography information for Catherine West

1005715

registered interest
date	12/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Sapropterin
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what estimate his Department has made of the financial cost offset to the NHS including savings to the NHS from reduced acquisition costs of food supplements of commissioning Kuvan for the treatment of phenylketonuria.
tabling member constituency	Hornsey and Wood Green
tabling member printed	Catherine West
uin	190519
answer	answer is ministerial correction date of answer 20/11/2018 answer text <p>NHS England has considered a policy for Kuvan (sapropterin) at the Clinical Priorities Advisory Group (CPAG) meeting on 6/7 November. Whilst NHS England did make an estimate of the current cost of protein supplements and a potential reduction in their use if Kuvan were prescribed, this cost was not included in the analysis because commissioning responsibility for supplements rests with clinical commissioning groups and it would be unlikely that NHS England would be able to realise these savings. The cost of the potential reduction in protein supplements is also relatively modest compared to the cost of Kuvan.</p><p> </p><p>In line with its published process, the recommendations from CPAG will be considered by the Specialised Commissioning Oversight Group and the Specialised Services Commissioning Committee. A decision about whether or not Kuvan has been prioritised for funding will be published in due course.</p><p> </p><p>The National Institute for Health and Care Excellence (NICE) is currently developing technology appraisal guidance for the National Health Service on the use of Kuvan for the treatment of phenylketonuria. In developing technology appraisal guidance, NICE takes into account all the health and publicly funded social care related costs and benefits associated with the treatment, potentially including any costs from NHS funded treatments that can be avoided such as food supplements. The NICE appraisal of Kuvan is now underway and NICE expects to publish final guidance next year.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 190518 question first answered 20/11/2018 15:25:36 answering member 4067 label Biography information for Steve Brine
tabling member	4523 label Biography information for Catherine West

1005716

registered interest
date	12/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Rare Diseases: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether a single technology appraisal process or a highly specialised technology appraisal process is used for (a) phenylketonuria and (b) other rare diseases.
tabling member constituency	Hornsey and Wood Green
tabling member printed	Catherine West
uin	190520
answer	answer is ministerial correction date of answer 20/11/2018 answer text <p>Medicines and other treatments being considered for assessment by the National Institute for Health and Care Excellence (NICE) are considered through an established topic selection process to ensure that they are suitable for referral to NICE and that they are routed to the most appropriate process within NICE. The topic selection process includes consideration of topic against published criteria and consultation with stakeholders. Most new medicines are referred for assessment through NICE’s technology appraisal programme though NICE also operates a separate highly specialised technology evaluation programme for a small number of very high cost drugs for the treatment of very rare diseases. Following consideration through the topic selection process, NICE is currently developing guidance on two drugs for the treatment of phenylketonuria through its technology appraisal programme.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 20/11/2018 15:26:35 answering member 4067 label Biography information for Steve Brine
tabling member	4523 label Biography information for Catherine West

1003616

registered interest
date	09/11/2018
answering body	Treasury
answering dept id	14
answering dept short name	Treasury
answering dept sort name	Treasury
hansard heading	Financial Services: Climate Change
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Chancellor of the Exchequer, what discussions he has had with the Governor of the Bank of England on managing the risk to the financial system posed by climate change.
tabling member constituency	Hornsey and Wood Green
tabling member printed	Catherine West
uin	189774
answer	answer is ministerial correction date of answer 19/11/2018 answer text <p>Treasury Ministers have meetings with a variety of public and private organisations, including the Bank of England, as part of the process of policy development.</p><p> </p><p>Details of ministerial meetings with external organisations are published quarterly at: <a href="https://www.gov.uk/government/collections/hmt-ministers-meetings-hospitality-gifts-and-overseas-travel" target="_blank">https://www.gov.uk/government/collections/hmt-ministers-meetings-hospitality-gifts-and-overseas-travel</a></p><p> </p><p>Green Finance is an important area of collaboration with the Bank of England, and we welcome the Bank’s recent announcement to set out, for consultation, supervisory expectations for banks and insurers to consider climate risks in their approach.</p> answering member constituency Salisbury answering member printed John Glen grouped question UIN 189843 question first answered 19/11/2018 16:10:52 answering member 4051 label Biography information for John Glen
tabling member	4523 label Biography information for Catherine West

1003617

registered interest
date	09/11/2018
answering body	Treasury
answering dept id	14
answering dept short name	Treasury
answering dept sort name	Treasury
hansard heading	Financial Services: Climate Change
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Chancellor of the Exchequer, what discussions he has had with the Governor of the Bank of England on the effect of climate change on the Bank’s ability to preserve macroeconomic stability.
tabling member constituency	Hornsey and Wood Green
tabling member printed	Catherine West
uin	189842
answer	answer is ministerial correction date of answer 19/11/2018 answer text <p>Treasury Ministers have meetings with a variety of public and private organisations, including the Bank of England, as part of the process of policy development.</p><p> </p><p>Details of ministerial meetings with external organisations are published quarterly at: <a href="https://www.gov.uk/government/collections/hmt-ministers-meetings-hospitality-gifts-and-overseas-travel" target="_blank">https://www.gov.uk/government/collections/hmt-ministers-meetings-hospitality-gifts-and-overseas-travel</a></p><p> </p><p>Green Finance is an important area of collaboration with the Bank of England, and we welcome the Bank’s recent announcement to set out, for consultation, supervisory expectations for banks and insurers to consider climate risks in their approach.</p> answering member constituency Salisbury answering member printed John Glen question first answered 19/11/2018 16:00:52 answering member 4051 label Biography information for John Glen
tabling member	4523 label Biography information for Catherine West

1003618

registered interest
date	09/11/2018
answering body	Treasury
answering dept id	14
answering dept short name	Treasury
answering dept sort name	Treasury
hansard heading	Financial Services: Climate Change
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Chancellor of the Exchequer, what discussions he has had with the Governor of the Bank of England on the Bank’s role in mobilising finance for the low-carbon transition.
tabling member constituency	Hornsey and Wood Green
tabling member printed	Catherine West
uin	189843
answer	answer is ministerial correction date of answer 19/11/2018 answer text <p>Treasury Ministers have meetings with a variety of public and private organisations, including the Bank of England, as part of the process of policy development.</p><p> </p><p>Details of ministerial meetings with external organisations are published quarterly at: <a href="https://www.gov.uk/government/collections/hmt-ministers-meetings-hospitality-gifts-and-overseas-travel" target="_blank">https://www.gov.uk/government/collections/hmt-ministers-meetings-hospitality-gifts-and-overseas-travel</a></p><p> </p><p>Green Finance is an important area of collaboration with the Bank of England, and we welcome the Bank’s recent announcement to set out, for consultation, supervisory expectations for banks and insurers to consider climate risks in their approach.</p> answering member constituency Salisbury answering member printed John Glen grouped question UIN 189774 question first answered 19/11/2018 16:10:51 answering member 4051 label Biography information for John Glen
tabling member	4523 label Biography information for Catherine West